BridgeBio Pharma (BBIO) Invested Capital (2019 - 2025)
BridgeBio Pharma (BBIO) has disclosed Invested Capital for 7 consecutive years, with -$79.3 million as the latest value for Q4 2025.
- Quarterly Invested Capital rose 91.31% to -$79.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$79.3 million through Dec 2025, up 91.31% year-over-year, with the annual reading at -$79.3 million for FY2025, 91.31% up from the prior year.
- Invested Capital hit -$79.3 million in Q4 2025 for BridgeBio Pharma, down from $74.3 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $358.1 million in Q1 2021 to a low of -$1.8 billion in Q2 2025.
- Historically, Invested Capital has averaged -$870.5 million across 5 years, with a median of -$1.1 billion in 2022.
- Biggest five-year swings in Invested Capital: tumbled 13126.74% in 2022 and later surged 106.09% in 2025.
- Year by year, Invested Capital stood at -$867.0 million in 2021, then tumbled by 43.41% to -$1.2 billion in 2022, then dropped by 8.02% to -$1.3 billion in 2023, then skyrocketed by 32.05% to -$912.6 million in 2024, then skyrocketed by 91.31% to -$79.3 million in 2025.
- Business Quant data shows Invested Capital for BBIO at -$79.3 million in Q4 2025, $74.3 million in Q3 2025, and -$1.8 billion in Q2 2025.